Exosomes · Lesson 14 of 18 · 3 min

How are exosomes administered? Routes, distribution and the dosing problem

The concepts behind exosome delivery: systemic versus local routes, where vesicles travel in the body, and why dosing has no universal standard.

A gloved hand pipetting into small vials on a lab bench

Key takeaways.

  • Route choice follows the goal: systemic delivery for widespread disease, local delivery for a focal target.
  • After intravenous delivery, exosomes reach the lungs first and a significant fraction may be retained there.
  • There is no universal standard for quantifying an exosome dose.
  • Doses defined by particle count, protein content or activity cannot be directly compared.
  • Exosomes are fragile, and poor storage or handling can destroy their activity.
  • Exosomes are not FDA-approved for therapeutic use by any route.

Route follows the therapeutic goal

Delivery matters as much as the product. An exosome preparation that never reaches its target tissue, or that is damaged before use, cannot be expected to do anything.

Systemic intravenous delivery is studied when disease is widespread, when the aim is a body-wide anti-inflammatory or immune effect, or when the target cannot be reached by direct injection. Local delivery is studied when the target is a specific accessible tissue.

Where exosomes go after intravenous delivery

Distribution is not random. Intravenously delivered exosomes travel first to the lungs, the first capillary bed they meet. Imaging studies with labeled exosomes show marked accumulation in lung tissue within minutes.

For lung conditions, this is the intended destination. For other targets, lung retention reduces the amount available to the rest of the body. This is one reason route selection is treated as a pharmacokinetic decision.

The dosing problem

A conventional drug is dosed by mass. Exosomes cannot be meaningfully dosed that way, because total mass does not separate vesicles from co-isolated material.

Instead, preparations are measured by surrogates: particle number, protein content, marker expression or functional activity. Each captures something different, and they cannot be converted into one another. A dose in one study cannot be readily compared with a dose in another.

Handling and combinations

Exosomes depend on an intact lipid membrane and functional cargo. Improper storage or handling can damage membranes, denature proteins and cause aggregation.

Exosomes are also combined with other regenerative and aesthetic modalities. The course distinguishes combinations with a research rationale from those marketed on speculation. Exosome therapies are not FDA-approved for therapeutic use.

Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.

Exosomes: 0 of 18 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • Route selection by application
  • Storage, thawing and preparation procedures
  • Dosing metrics and how to read a product label
  • Quality control at the point of administration
  • Designing combination approaches

Common questions.

Is there a standard dose for exosomes?
No. There is no universal quantification standard. Studies report dose by particle number, protein content or functional activity, and these measures are not interchangeable.
Where do exosomes go after an IV infusion?
They reach the lungs first, where a significant fraction may be retained during the first pass. This reduces what is available for other tissues.
Why does handling matter so much?
Exosome activity depends on intact membranes and functional proteins and nucleic acids. Freeze-thaw damage and other handling errors can destroy that activity before use.

Sources

  • Wiklander, O. P. B., et al. (2015). Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. Journal of Extracellular Vesicles, 4, 26316.
  • Théry, C., et al. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018). Journal of Extracellular Vesicles, 7(1), 1535750.
  • Phinney, D. G., & Pittenger, M. F. (2017). Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells, 35(4), 851-858.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.